Welcome to our dedicated page for DiaMedica Therapeutics SEC filings (Ticker: DMAC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DiaMedica Therapeutics Inc. filings document a clinical-stage biopharmaceutical issuer developing DM199 for preeclampsia, fetal growth restriction and acute ischemic stroke. Form 8-K reports cover operating and financial results, business updates, clinical and regulatory disclosures, material agreements and executive leadership changes.
The company’s proxy materials describe shareholder meeting matters, board governance, executive compensation and equity award information. Other filings address capital-structure activity, including at-the-market common share sales arrangements, as well as Regulation FD disclosures and risk-language tied to DM199 development and regulatory interactions.
Pauls Dietrich John reported acquisition or exercise transactions in this Form 4 filing.
DiaMedica Therapeutics Inc. reported that President & CEO Dietrich John Pauls received a grant of 60,200 restricted stock units (RSUs) of voting common shares at no stated per-share cost. These RSUs vest in four equal annual installments on the first through fourth anniversaries of the grant date, contingent on continued service. Following this award, Pauls holds 128,791 voting common shares, including 1,749 shares issuable upon settlement of deferred share units granted under the company’s Deferred Share Unit Plan.
DiaMedica Therapeutics Inc. reported a larger loss for the quarter and first half of 2026 as it continued to advance its lead drug candidate DM199 in preeclampsia (PE), fetal growth restriction (FGR) and acute ischemic stroke (AIS). For the six months ended June 30, 2026, the company recorded a net loss of $20.2 million, compared with $15.4 million a year earlier, driven mainly by higher research and development spending.
R&D expenses rose to $16.1 million for the first half of 2026 from $11.5 million, reflecting expansion of the ReMEDy2 AIS trial globally, additional reproductive toxicity testing to support the PE program, increased manufacturing activity, and higher share-based compensation. General and administrative expenses were relatively stable at $4.8 million versus $4.7 million. Operating cash outflow was $17.2 million in the first half.
As of June 30, 2026, DiaMedica held $43.5 million in cash, cash equivalents and marketable securities, working capital of $37.7 million, and shareholders’ equity of $38.3 million. Management expects these resources to fund planned operations for at least 12 months, while continuing the Phase 2 PE trial and the Phase 2/3 ReMEDy2 AIS trial, where enrollment for the interim analysis has reached 85% of the 200-participant threshold.
DiaMedica Therapeutics, a clinical-stage biopharmaceutical company focused on ischemic diseases, reported second quarter 2026 results and clinical progress for DM199. The company highlighted positive interim Part 1a Phase 2 data in women with preeclampsia, where mid-dose cohorts showed reductions in maternal blood pressure and uterine artery pulsatility index, supporting this dose range for further evaluation in early-onset preeclampsia and fetal growth restriction studies. A first fetal growth restriction cohort has been enrolled, and a concurrent open-label three-dose Phase 2 study in early-onset preeclampsia in North America and the United Kingdom is being prepared.
For the quarter ended June 30, 2026, research and development expenses were $8.2 million versus $5.8 million in 2025, and general and administrative expenses were $2.3 million versus $2.2 million. Net loss for the quarter was $10.1 million, compared with $7.7 million a year earlier, or $0.19 per share versus $0.18. For the first six months of 2026, net loss was $20.2 million versus $15.4 million in 2025. As of June 30, 2026, cash and cash equivalents were $5.1 million and marketable securities were $38.4 million, with total assets of $45.0 million and shareholders’ equity of $38.3 million. Net cash used in operating activities for the first half of 2026 was $17.2 million.
DiaMedica Therapeutics Inc. director Randall Michael Giuffre received a grant of stock options representing 40,412 Voting Common Shares. The options have an exercise price of $5.84 per share, expire on June 1, 2036, and are scheduled to vest in four equal quarterly installments.
DiaMedica Therapeutics Inc. director Richard Kuntz reported a grant of stock options. He received options covering 40,412 Voting Common Shares at an exercise price of $5.84 per share, expiring on June 1, 2036. These options are scheduled to vest in four equal quarterly installments, and following this grant he holds 40,412 derivative securities directly.
DiaMedica Therapeutics Inc. director Daniel J. O'Connor received a grant of stock options to acquire 40,412 voting common shares. The options have an exercise price of $5.84 per share, expire on June 1, 2036, and are scheduled to vest in four equal quarterly installments. Following this grant, he holds options for 40,412 shares directly.
DiaMedica Therapeutics Inc. director Tanya Lewis received a grant of stock options as part of her compensation. She was awarded 40,412 stock options with a conversion or exercise price of $5.84 per share, giving her the right to buy Voting Common Shares at that price.
The options are scheduled to vest in four equal quarterly installments and will expire on June 1, 2036. Following this grant, she holds 40,412 derivative securities related to this award, indicating a routine, compensation-related acquisition rather than an open-market purchase or sale.
DiaMedica Therapeutics Inc. director Charles Pauling Semba received a new stock option grant. He was awarded options for 40,412 shares of Voting Common Shares at an exercise price of $5.84 per share. These options are scheduled to vest in four equal quarterly installments and expire on June 1, 2036.
DiaMedica Therapeutics Inc. director James T. Parsons received a stock option grant reported on a Form 4. He was awarded options to purchase 51,189 Voting Common Shares at an exercise price of $5.84 per share, expiring on June 1, 2036.
The grant is classified as a compensation-related award, not an open-market purchase, and is held directly. According to the disclosure, the options are scheduled to vest in four substantially equal quarterly installments, meaning his ability to exercise them will phase in over time.
DiaMedica Therapeutics Inc. President & CEO Dietrich John Pauls received a grant of stock options covering 380,000 Voting Common Shares. The options have an exercise price of $5.84 per share and expire on June 1, 2036.
The award is compensation-related rather than an open-market trade. It is scheduled to vest 25% on the one-year anniversary of the grant date, with the remaining options vesting in twelve equal quarterly installments. Following this grant, he holds 380,000 stock options directly.